Pivotal role of cd38 biomarker in combination with CD24, EpCAM, and ALDH for identification of H460 derived lung cancer stem cells

Journal of Stem Cells

Volumn 6, Issue 1, 2011, Pages 9-20

  Karimi Busheri, Feridoun ^a   Zadorozhny, Victoria ^a   Li, Tony ^a   Lin, Helen ^a   Shawler, Daniel L ^a   Fakhrai, Habib ^a  

^a NovaRx Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD133 ANTIGEN; CD24 ANTIGEN; CD38 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; TUMOR MARKER; ALDEHYDE DEHYDROGENASE ISOENZYME 1; CD24 PROTEIN, HUMAN; CD38 PROTEIN, HUMAN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; ISOENZYME; MEMBRANE PROTEIN; MESSENGER RNA; RETINAL DEHYDROGENASE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STEM CELL; CARCINOGENICITY; CELL ISOLATION; CELL SUBPOPULATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; DNA MICROARRAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENETICS; LUNG TUMOR; METABOLISM; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

MUS;

ANIMALS; ANTIGENS, CD24; ANTIGENS, CD38; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION MOLECULES; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETINAL DEHYDROGENASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84867298297     PISSN: 15568539     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Voog J, Jones DL. Stem cells and the niche: a dynamic duo. Cell Stem Cell 2010; 6(2):103-115.
2. Park CY, Tseng D, Weissman, IL. Cancer stem celldirected therapies: recent data from the laboratory and clinic. Mol. Ther. 2009;17(2):219-230.
3. Weissman, IL. Shizuru, JA. The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. Blood 2008;112(9):3543-3553.
4. Karimi-Busheri, F, Rasouli-Nia A, Mackey, JR, Weinfeld, M. Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res.2010;12(3):R31.
5. Stuelten, CH, Mertins, SD, Busch, JI, et al. Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 2010;28(4):649-660.
6. Goodell, MA, Brose, K, Paradis, G, et al. Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 1996;183(4):1797-1806.
7. Al-Hajj, M, Wicha, M S, Benito-Hernandez, A, et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003;100(7):3983-3988.
8. Schatton, T, Frank, NY, and Frank, MH. Identification and targeting of cancer stem cells. Bioessays 2009;31(10):1038-1049.
9. Hadjipanayis, CG. Van Meir, EG. Tumor initiating cells in malignant gliomas: biology and implications for therapy. J. Mol. Med. 2009;87:363-374.
10. Liu, S, Wicha, MS. J. Clin. Oncol. Targeting breast cancer stem cells. 2010;28(25): 4006-4012.
11. Jemal, A, Siegel, R, Xu, J, Ward, E. Cancer Statistics, 2010. CA Cancer J. Clin. 2010;60(5):277-300.
12. Salcido, CD, Larochelle, A., Taylor, B, et al. Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br. J. Cancer 2010;102(11):1636-1644.
13. Kratz, JR, Yagui-Beltran, A, Jablons, DM. Cancer stem cells in lung tumorigenesis. Ann. Thorac. Surg. 2010;89(6):S2090-2095.
14. Bertolini, G, Roz, L, Perego, P, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. U. S. A 2009;106(38):16281-16286.
15. Ho, MM, Ng, AV, Lam, S, Hung, JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007;67(10):4827-4833.
16. Gorelik, E, Lokshin, A, and Levina, V. Lung cancer stem cells as a target for therapy. Anticancer Agents Med. Chem. 2010;10(2):164-171.
17. Pine, SR, Marshall, B, Varticovski, L. Lung cancer stem cells. Dis. Markers 2008;24(4-5):257-266.
18. Cox, CV, Diamanti, P, Evely, RS, et al. Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood 2009;113(14):3287-3296.
19. Prestegarden, L. Enger, PO. Cancer Stem Cells in the Central Nervous System - A Critical Review. Cancer Res. 2010;70(21):8255-8258.
20. Monzani, E, Facchetti, F, Galmozzi, E, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer 2007;43(5):935-946.
21. Hilbe, W, Dirnhofer, S, Oberwasserlechner, F, et al. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J. Clin. Pathol. 2004;57(9):965-969.
22. Eramo, A, Lotti, F, Sette, G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death. Differ. 2008;15(3);504-514.
23. Tirino, V, Camerlingo, R, Franco, R, et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur. J. Cardiothorac. Surg. 2009;36(3):446-453.
24. Wang, B, Yang, H, Huang, YZ, et al. Biologic characteristics of the side population of human small cell lung cancer cell line H446. Chin J. Cancer 2010;29:254-260.
25. Salnikov, AV, Groth, A, Apel, A, et al. Targeting of cancer stem cell marker epcam by bispecific antibody epcamxcd3 inhibits pancreatic carcinoma. J. Cell Mol. Med. 2009;13(9B):4023-33.
26. Meng, X, Li, M, Wang, X, et al. Both CD133+ and C CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci. 2009;100(6):1040-1046.
27. Kristiansen, G, Schluns, K, Yongwei, Y, et al. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br. J. Cancer 2003;88(2):231-236.
28. Lee, HJ, Choe, G, Jheon, S, et al. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. J. Thorac. Oncol. 2010;5(5):649-657.
29. Karimi-Busheri, F, Zadorozhny, V, Shawler, DL, and Fakhrai, H. The stability of breast cancer progenitor cells during cryopreservation: Maintenance of proliferation, self-renewal, and senescence characteristics. Cryobiology 2010;60(3):308-314.
30. Parson, W, Kirchebner, R, Muhlmann, R, et al. Cancer cell line identification by short tandem repeat profiling: power and limitations. FASEB J. 2005;19(3):434-436.
31. Nemunaitis, J, Dillman, RO, Schwarzenberger, PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense genemodified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006;24(29):4721-4730.
32. Nemunaitis, J, Nemunaitis, M, Senzer, N, et al. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther. 2009;16(8):620-624.
33. Spiro, SG, Tanner, NT, Silvestri, GA, et al. Lung cancer: progress in diagnosis, staging and therapy. Respirology 2010;15(1):44-50.
34. Burger, PE, Gupta, R, Xiong, X, et al. High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells. Stem Cells 2009;27(9):2220-2228.
35. Jiang, F, Qiu, Q, Khanna, A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009;7(3):330-338.
36. Prasmickaite, L, Engesaeter, BO, Skrbo, N, Hellenes, T, et al. Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS. One 2010;5(5):e10731.
37. van der Gun, BT, Melchers, LJ, Ruiters, MH, et al. EpCam in carcinogenesis: The good, the bad, or the ugly. Carcinogenesis 2010;31(11):1913-21.
38. Munz, M, Baeuerle, PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 2009;69(14):5627-5629.
39. Cheng, JX, Liu, BL, Zhang, X. How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat. Rev. 2009;35(5):403-408.
40. Bauer, N, Fonseca, AV, Florek, M, et al. New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). Cells Tissues. Organs 2008;188(1-2):127-138.
41. Ji, J, Black, KL, Yu, JS. Glioma stem cell research for the development of immunotherapy. Neurosurg. Clin. N. Am. 2010;21(1):159-166.
42. Yingling, JM, Datto, MB, Wong, C, et al. Tumor suppressor Smad4 is a transforming growth factor beta inducible DNA binding protein. Mol. Cell Biol. 1997;17(12):7019-7028.
43. Miraglia, S, Godfrey, W, Yin, AH, et al. A novel fivetransmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997;90(12):5013-5021.
44. Lee, JH, Kim, SH, Lee, ES, and Kim, YS. CD24 overexpression in cancer development and progression: a meta-analysis. Oncol. Rep. 2009;22(5):1149-1156.
45. Kristiansen, G, Pilarsky, C, Pervan, J, et al. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004;58(2):183-192.
46. Higuchi, Y, Zeng, H, Ogawa, M. CD38 expression by hematopoietic stem cells of newborn and juvenile mice. Leukemia 2003;17(1):171-174.
47. Deaglio, S, Mehta, K, and Malavasi, F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk. Res. 2001;25(1):1-12.